Agilent 2026 Q3 revenue, EPS top guidance on core growth

Agilent Technologies (NYSE: A ) released third-quarter financial results and hosted an earnings call on Wednesday.

Read the complete transcript below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Agilent Technologies Inc. reported Q3 2026 revenue of $1.88 billion, a 7.3% increase on a core basis, surpassing guidance by 140 basis points.

Operating margin, excluding tariff refunds, was 27.2%, with EPS at $1.56 (ex-tariff refund), exceeding guidance by $0.06.

The IGNITE operating system significantly contributed to operational efficiency and margin improvements.

Pharma sector grew 12%, driven by GLP-1 demand and Advanced Therapeutics division expansion.

China recorded 9% growth, surpassing flat expectations, due to strong pharma and food demand.

Future guidance indicates full-year revenue growth of 5.8% to 6% with EPS between $6.18 to $6.21, reflecting increased confidence in end markets.

Strategic initiatives include expanding the Altura column family and leveraging the IGNITE system for operational enhancements.

Reshoring in pharma and semiconductor sectors expected to contribute significantly to future growth.

Management highlighted ongoing digital transformation and sustainability efforts, receiving recognition for their initiatives.

Full Transcript OPERATOR Ladies and gentlemen, thank you for joining us and welcome to the Q3 2026 Agilent Technologies Inc.

Earnings Conference Call.

After today's prepared remarks, we will host a question and answer session.

If you would like to ask a question, please raise your hand.

If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute.

I will now hand the call over to Tejas Savant, Head of Investor Relations.

You may begin.

Tejas Savant, Head of Investor Relations Thank you and welcome everyone to Agilent's conference call for the third quarter of fiscal year 2026.

With me on the line are CEO Parik McDonnell and CFO Adam Elenoff.

Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group, Angelika Reiman, President of the Agilent Cross Lab Group, and Mike Zhang, President of the Applied Markets Group.

This presentation is being webcast live.

The press release for our third quarter financial results, investor presentation and information to supplement today's discussion along with the recording of this webcast are available on our website at investor.agilent.com.

Today's comments will refer to non-GAAP financial measures.

Non-GAAP measures are supplemental and should not be considered a substitute for GAAP results.

You'll find the most directly comparable GAAP financial metrics and reconciliations in the press release and on our website.

Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core or organic constant-currency basis.

All references to profitability metrics are on a non-GAAP basis.

Core or organic constant-currency revenue growth is adjusted for the impact of currency exchange rates and any acquisitions and divestitures completed within the past 12 months.

Guidance is based on forecasted exchange rates.

During this call we will make forward-looking statements about the financial performance of the company.

These statements are subject to risks and uncertainties and are only valid as of today.

Agilent assumes no obligation to update them.

Please refer to the company's recent SEC filings for a more detailed description of the risks and other factors that would cause our performance to differ from these forward-looking statements.

And now I'd like to turn the call over to Parik.